NeOnc Showcases Two Brain Cancer Drug Programs at SNO as FDA Meetings Approach
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
NeOnc Technologies Holdings (NASDAQ: NTHI) is presenting updated findings from two investigational brain cancer programs at the Society for Neuro-Oncology meeting.
NEO100's Phase 2a study reported 48.9% six-month progression-free survival versus a 20% historical benchmark (p=0.0047), with median overall survival of 26.1 months in 24 patients. No treatment-related Grade 3 or higher adverse events were reported. NEO212 completed Phase 1 dose escalation with no observed myelosuppression, or suppression of blood-cell production, and two objective responses; both patients remained on treatment for more than 20 months.
An FDA meeting in early January 2027 will address NEO100's potential accelerated approval pathway and proposed Phase 3 trial. A November 23 meeting will address NEO212's next-stage development. Recent insider purchases and an Abu Dhabi research memorandum accompany the clinical updates.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointNEO100 six-month progression-free survival reached 48.9% versus a 20% historical benchmark (p=0.0047).
- Moderate pointNEO212 Phase 1 dose escalation is complete, with no observed suppression of blood-cell production.
- Moderate pointAbu Dhabi memorandum establishes a framework for CNS oncology research, clinical collaboration, training and real-world evidence.
- Minor pointNEO100 median overall survival was 26.1 months; estimated survival was 86.7%, 61.5% and 54.7% at six, 12 and 24 months.
- Minor pointNEO100 safety findings included no treatment-related Grade 3 or higher events, serious adverse events or adverse-event discontinuations.
8 minor points
- Minor pointFive NEO100 patients remained on treatment at the interim database lock.
- Minor pointNEO100 compassionate use: treating physicians reported independent breathing and leg movement in a critically ill three-year-old.
- Minor pointNEO212 objective responses occurred in recurrent glioblastoma and lung-cancer brain metastasis; both patients remained on treatment over 20 months.
- Minor point. Forward-looking: it has not happened yet and may not happen.NEO100 proposed Phase 3 trial would compare NEO100 with investigator's-choice chemotherapy, measuring overall survival.
- Minor point. Forward-looking: it has not happened yet and may not happen.NEO212 proposed randomized Phase 2 design covers brain metastases, IDH1-mutant astrocytoma and recurrent IDH1-wildtype glioblastoma.
- Minor pointCEO open-market purchases totaled approximately $333,100 for 80,000 shares on November 9–11; direct holdings reached 3,333,000 shares.
- Minor pointChief Medical Officer Chen purchased 5,016 shares through his IRA for approximately $20,000.
- Minor point. Forward-looking: it has not happened yet and may not happen.Four analyst Buy ratings carried reported price targets ranging from $13 to $20.
Negative
- Moderate point. Forward-looking: it has not happened yet and may not happen.NEO100 accelerated approval pathway remains potential, with FDA discussion scheduled for early January 2027.
- Moderate pointAbu Dhabi collaboration is at the memorandum-of-understanding framework stage.
- Minor point. Forward-looking: it has not happened yet and may not happen.NEO212 next-stage development awaits November 23 FDA discussion of populations, dosing, endpoints and proposed Phase 2 design.
Key Figures
- Six-month progression-free survival
- 48.9%
- NEO100 Phase 2a; versus a prespecified historical benchmark of 20%
- P-value
- p=0.0047
- NEO100 Phase 2a six-month progression-free survival
- Median overall survival
- 26.1 months
- NEO100 Phase 2a
- Efficacy population
- 24 patients
- NEO100 Phase 2a
- Objective responses
- 2
- NEO212 Phase 1: one recurrent glioblastoma and one lung-cancer brain metastasis
- Time on treatment
- More than 20 months
- Both patients with reported NEO212 objective responses
- NEO100 FDA meeting
- Early January 2027
- Type B End-of-Phase meeting
- NEO212 FDA meeting
- November 23
- End-of-Phase 1 Type B meeting
Historical Context
-
FDA meeting set to discuss NEO100's potential pathway and a randomized Phase 3 trial.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
pharmacokinetics medical
myelosuppression medical
accelerated approval pathway regulatory
overall survival medical
compassionate-use medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
DENVER, Nov. 13, 2026 (GLOBE NEWSWIRE) -- (247MarketNews) — NeOnc Technologies Holdings (NASDAQ: NTHI) reaches an important clinical-development milestone today as it presents updated findings from two investigational brain cancer programs at the 31st Annual Meeting of the Society for Neuro-Oncology (SNO) in Philadelphia. The presentations put the company's intranasal NEO100 and oral NEO212 programs in focus, with additional clinical evidence arriving as NeOnc prepares for important FDA discussions and continues to attract substantial insider buying.
The first presentation, abstract CTNI-26, titled Durable Radiographic Remission and Prolonged Survival with Intranasal NEO100 in Recurrent WHO Grade III/IV IDH1-Mutant Astrocytoma, provides updated Phase 1/2a and compassionate-use experience. Presented by Chief Medical Officer Thomas C. Chen, MD, PhD, the findings are particularly important because they build on previously reported survival and progression-free survival results in a difficult-to-treat patient population.
In August, NeOnc reported that its Phase 2a study achieved six-month progression-free survival of
The company reported no treatment-related Grade 3 or higher adverse events, treatment-related serious adverse events or discontinuations due to treatment-related adverse events. These results provide the clinical foundation for NeOnc's effort to advance NEO100 toward a potential accelerated approval pathway.
The compassionate-use component provides an additional dimension. In October, NeOnc reported that a critically ill three-year-old boy receiving investigational NEO100 in Abu Dhabi began breathing independently without ventilator support and moving his legs, according to his treating physicians.
The second presentation, abstract CTNI-27, examines oral NEO212 in temozolomide-resistant recurrent glioblastoma and brain metastases. Its focus is Phase 1 safety, pharmacokinetics and early activity.
NEO212 combines temozolomide with perillyl alcohol in an oral formulation intended to improve drug delivery to the brain and address temozolomide resistance. NeOnc reports that Phase 1 dose escalation is complete, with no observed myelosuppression. The company also disclosed two objective responses: one in recurrent glioblastoma and another in a patient with lung-cancer brain metastasis. Both patients reportedly remained on treatment for more than 20 months.
These observations are particularly interesting given the hematologic toxicity associated with conventional temozolomide. NEO212 now represents a second potential clinical opportunity, distinct from NEO100's intranasal delivery strategy.
NeOnc’s regulatory calendar is becoming increasingly important. The FDA granted a Type B End-of-Phase meeting scheduled for early January 2027 to discuss NEO100's potential accelerated approval pathway, a proposed randomized Phase 3 trial and the adequacy of its nonclinical safety package. The proposed NEO100-012 study would compare intranasal NEO100 with investigator's-choice chemotherapy, using overall survival as its primary endpoint.
NEO212 has its own upcoming regulatory milestone: an End-of-Phase 1 Type B FDA meeting scheduled for November 23. NeOnc intends to discuss patient populations, dosing, endpoints and a proposed randomized Phase 2 design covering brain metastases, IDH1-mutant astrocytoma and recurrent IDH1-wildtype glioblastoma.
The clinical developments coincide with continued insider buying. CEO Amir Heshmatpour reported approximately
Other factors adding to investor interest include four analyst Buy ratings, with reported price targets ranging from
International expansion is another developing opportunity. An October memorandum of understanding with the Department of Health – Abu Dhabi establishes a framework for CNS oncology research, clinical collaboration, training and real-world evidence, building on previously granted investigational authorizations for NEO100 and NEO212.
For investors, today's SNO presentations matter because they bring two distinct clinical programs into the spotlight at the same time. The next tests are whether the updated NEO100 findings strengthen the case for further development, whether NEO212's early safety and activity observations translate into controlled clinical evidence, and how the FDA responds to both development strategies.
About 247MarketNews
In today's fast-moving markets, visibility is everything and 247MarketNews provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you're an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 247MarketNews delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247marketnews.com to discuss how 247MarketNews can help accelerate your company’s visibility and valuation trajectory.
PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 247MarketNews is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.
Important Editorial Note: 247MarketNews highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.
CONTACT:
247MarketNews
Editor@247marketnews.com
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did NeOnc's NEO100 brain cancer study show?
NEO100 reported 48.9% six-month progression-free survival against a prespecified historical benchmark of 20% (p=0.0047). Median overall survival was 26.1 months. The efficacy population comprised 24 patients with IDH1-mutant astrocytoma: 21 with grade 4 disease and three with grade 3 disease.
When are NeOnc's FDA meetings for NEO100 and NEO212?
NEO100's Type B End-of-Phase FDA meeting is scheduled for early January 2027, and NEO212's End-of-Phase 1 Type B meeting is scheduled for November 23. NEO100 discussions will cover a potential accelerated approval pathway, a proposed randomized Phase 3 trial and the adequacy of its nonclinical safety package.